Review summary
Teaching objective: Disability-competent primary care for a man blind since childhood (introductions and spoken orientation, describing each step of the examination, accessible electronic documents, braille and audio medication labels, and fall prevention), recovery-oriented care for an opioid use disorder in sustained remission for three decades (naloxone, relapse-prevention discussion, and a plan for any future pain that protects his recovery, in non-stigmatizing language), depression screening and a structured safety assessment, and eye care for blind eyes limited to what can help him (comfort, pain, and the place of pressure checks) on the CMID glaucoma and depression monographs with AAO, ASAM, and VA/DoD guidance.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| September 23, 1930 | Born Ray Charles Robinson in Albany, Georgia. | CLM-0001 |
| 1935 | Began to lose his sight; his younger brother drowned the same year. | CLM-0003, CLM-0007 |
| 1937 | Blind by age seven; enrolled at the Florida School for the Deaf and Blind. | CLM-0003 |
| 1945 | His mother died. | CLM-0007 |
| 1964 | Arrested for heroin possession; later admitted addiction since the late 1940s. | CLM-0005 |
| 1965 | Stopped heroin after rehabilitation at a California sanitarium. | CLM-0005, CLM-0006 |
| June 10, 2004 | Died at his home in Beverly Hills. | CLM-0002 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Ray Charles Robinson was born in Albany, Georgia, on September 23, 1930; his mother moved him as an infant to Greenville, a small town in north Florida. | confirmed | Ray Charles (1930-2004) supports |
| D | Ray Charles died at his home in Beverly Hills, California, on June 10, 2004, of acute liver disease, according to his spokesman. Record the death as a fact without detail; the episode records no liver diagnosis. |
confirmed | Ray Charles (1930-2004) supports Legendary musician Ray Charles dies at 73 supports |
| D | Charles began to lose his sight at about age five and was blind by age seven; after he was declared legally blind, he was enrolled at the Florida School for the Deaf and Blind in St. Augustine, where he remained for nine years. The anchor for the blindness of both eyes since childhood. The sources do not grade the residual vision; the record treats it as total blindness. |
confirmed | Ray Charles (1930-2004) supports Legendary musician Ray Charles dies at 73 supports |
| R | The cause of his blindness is uncertain. It is described as probably congenital juvenile glaucoma, and glaucoma is often mentioned as the cause, but Charles said that nothing was ever diagnosed. Retrospective interpretation; glaucoma is not coded as a diagnosis. |
possible | Ray Charles (1930-2004) supports Legendary musician Ray Charles dies at 73 disputes |
| D | In 1964 Charles was arrested for possession of heroin, and he later admitted that he had been addicted since the late 1940s. After a period of rehabilitation at a California sanitarium he stopped using drugs and received a five-year suspended sentence. His own public admission and the documented rehabilitation; the anchor for the synthetic opioid use disorder in sustained remission. |
confirmed | Ray Charles (1930-2004) supports |
| D | Charles struggled with heroin addiction for nearly 20 years and quit "cold turkey" in 1965, after an arrest at the Boston airport. He later became reluctant to discuss his drug use, fearing it would taint how people viewed his work. Supports the long remission and the recovery-oriented, non-stigmatizing approach in the episode. |
confirmed | Legendary musician Ray Charles dies at 73 supports |
| D | In the year Charles began to lose his sight, his younger brother drowned. His mother died in 1945. Family history; no cause of the mother's death is given. |
confirmed | Ray Charles (1930-2004) supports Legendary musician Ray Charles dies at 73 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Blindness of both eyes since childhood, no light perception; cause never diagnosed | active | confirmed | both_with_link | CLM-0003, CLM-0004 |
| S | Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment | active | confirmed | both_with_link | CLM-0005, CLM-0006 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-03-03 | Hemoglobin [Mass/volume] in Blood | 14.2 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-03 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-03 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-03-03 | Cholesterol [Mass/volume] in Serum or Plasma | 186 mg/dL Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-03-03 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-03-03 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 110 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-03-03 | Triglyceride [Mass/volume] in Serum or Plasma | 110 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-03-03 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-03-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-03-03 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
| S | 2026-03-03 | Total score [DAST-10] | 0 | http://loinc.org · 82667-7 |
| S | 2026-09-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-10-06 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
| S | 2026-10-06 | Total score [DAST-10] | 0 | http://loinc.org · 82667-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-03-03 | Body height | 178 cm | 8302-2 | S |
| 2026-03-03 | Body weight | 80 kg | 29463-7 | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 25.2 kg/m2 | 39156-5 | S |
| 2026-03-03 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-03-03 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-03-03 | Heart rate | 68 /min | 8867-4 | S |
| 2026-03-03 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-03-03 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-03-31 | Body height | 178 cm | 8302-2 | S |
| 2026-03-31 | Body weight | 80.2 kg | 29463-7 | S |
| 2026-03-31 | Body mass index (BMI) [Ratio] | 25.3 kg/m2 | 39156-5 | S |
| 2026-03-31 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-03-31 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-03-31 | Heart rate | 66 /min | 8867-4 | S |
| 2026-03-31 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-03-31 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-03-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-06-02 | Body height | 178 cm | 8302-2 | S |
| 2026-06-02 | Body weight | 79.8 kg | 29463-7 | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 25.2 kg/m2 | 39156-5 | S |
| 2026-06-02 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-06-02 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-06-02 | Heart rate | 68 /min | 8867-4 | S |
| 2026-06-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-02 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-01 | Body height | 178 cm | 8302-2 | S |
| 2026-09-01 | Body weight | 80 kg | 29463-7 | S |
| 2026-09-01 | Body mass index (BMI) [Ratio] | 25.2 kg/m2 | 39156-5 | S |
| 2026-09-01 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-09-01 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-09-01 | Heart rate | 66 /min | 8867-4 | S |
| 2026-09-01 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-01 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-06 | Body height | 178 cm | 8302-2 | S |
| 2026-10-06 | Body weight | 80.4 kg | 29463-7 | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 25.4 kg/m2 | 39156-5 | S |
| 2026-10-06 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-10-06 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-10-06 | Heart rate | 68 /min | 8867-4 | S |
| 2026-10-06 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-06 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S In sustained remission from opioid use disorder: no heroin or other opioid use for more than thirty years, without medication treatment; DAST-10 0 for the past year
- S Alcohol: AUDIT-C 2, below the risk threshold; no tobacco use
- S Professional musician who still performs and travels; lives in his own home, arranged so that he can move about it independently
- S Recovery supports: purposeful work, long-time colleagues, and friends; has not needed formal recovery services for many years and knows how to reach them
Functional status
- S Blind since childhood, with no light perception. Independent in all activities of daily living and instrumental activities using nonvisual methods; uses a screen reader and a smartphone voice assistant; uses a sighted guide in unfamiliar places
- S Falls: none in the past year and no fear of falling. Timed Up and Go 10 seconds, walking independently along the clinic corridor after a brief spoken orientation; steady gait; no fall in blood pressure on standing (128/78 seated, 126/78 standing)
- S Access needs: staff introduce themselves, say when they enter or leave the room, describe each step of the examination before touching him, and offer an arm rather than steering him. All written material as accessible electronic documents his screen reader can read; medicine labels in braille or audio
Mental status
- S Alert and oriented; warm, witty, and engaged; thought process organized; no signs of intoxication or withdrawal
- S Mood good; PHQ-9 score 2 with item 9 scored 0; no thoughts of suicide or self-harm
Structured safety assessment
This assessment is synthetic and does not convert historical behavior into a present-day fact.
Allergies and medications
Allergies
- S No known allergy
Medications
- S Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils
Procedures and immunizations
Procedures
- S Ophthalmic examination of the blind eyes for comfort and complications
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2025-10-20: High-dose influenza vaccine, 2025-2026 season
- S 2026-10-06: High-dose influenza vaccine, 2026-2027 season
- S 2026-10-06: Pneumococcal conjugate vaccine PCV20
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1937: Gradual loss of sight from about age five; blind by age seven; schooled at the Florida School for the Deaf and Blind (CLM-0003)
- R 1937: Cause of the childhood blindness never diagnosed, by his own account; congenital juvenile glaucoma is the cause most often suggested (CLM-0004)
- D 1965: Heroin addiction from the late 1940s, publicly admitted after an arrest in 1964; stopped in 1965 after rehabilitation at a California sanitarium (CLM-0005, CLM-0006)
Family history
- D mother: Died in 1945; cause not recorded in the cited source
- D brother: Younger brother died by drowning in early childhood
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Visit summaries, results, and medicine information delivered in an accessible electronic format, and medicine labels in braille or audio, by the four-week visit | 2026-03-31 | completed | Visit summaries sent as accessible documents; the pharmacy provides audio labels and a braille label on the naloxone |
| Naloxone at home and in his travel bag, with a tactile label, and the people he travels with shown how to use it, by the three-month visit | 2026-06-02 | completed | Naloxone in both places; travel staff shown how to use it |
| Stay in sustained remission, with no return to opioid use, through six months | 2026-09-01 | completed | No opioid use; DAST-10 0 at intake and no use reported at each visit |
| No falls through six months | 2026-09-01 | completed | No falls |
| A written plan for any future acute pain or surgery that uses non-opioid treatment first and builds in safeguards if an opioid is ever needed, by the six-month visit | 2026-09-01 | completed | Plan written with him and saved in an accessible format |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Disability-competent care at every visit: introductions and spoken orientation, describing each step of the examination, offering an arm for guiding, and all documents in an accessible electronic format | completed | GL-AAO-VISREHAB-2023 |
| Ophthalmology consultation to examine the blind eyes for comfort and complications and to advise on pressure checks and surveillance | completed | GL-AAO-POAG-2025, GL-CMID-2026 |
| Recovery-oriented care: ask about cravings, triggers, and any return to use at each visit in a non-judgmental way; naloxone at home and when traveling; recovery supports he can reach; and a written plan for any future pain | completed | GL-SUD-2021, GL-ASAM-OUD-2020 |
| Depression screening with the PHQ-9 at intake and at six months, PHQ-2 at the wellness visit, and a safety review with the 988 Suicide & Crisis Lifeline at each visit | completed | GL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024 |
| Medicine labeling: audio labels from the pharmacy, a braille label on the naloxone, and the same pharmacy for every prescription | completed | GL-AAO-VISREHAB-2023 |
| Fall prevention: CDC STEADI screen at each visit, keeping the home layout unchanged, and a sighted guide in unfamiliar places | completed | GL-AAO-VISREHAB-2023 |
Planned encounters
- 2026-03-03 — Establishing primary care: accessible care for a blind adult, recovery-oriented review, and depression and safety screening (ENC-001)
- 2026-03-31 — Four-week follow-up with ophthalmology consultation for the blind eyes (ENC-002)
- 2026-06-02 — Three-month review of recovery, accessibility, and fall prevention (ENC-003)
- 2026-09-01 — Six-month review with depression screening and a plan for any future pain (ENC-004)
- 2026-10-06 — Subsequent annual wellness visit (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Care-plan review)
- Progress note 05 — Annual Wellness Visit, Subsequent
- Ophthalmology referral
- Ophthalmology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Care-plan review) (XML)
- Progress note 05 — Annual Wellness Visit, Subsequent (XML)
- Ophthalmology referral (XML)
- Ophthalmology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Ray Charles (1930-2004) | New Georgia Encyclopedia (Georgia Humanities) | scholarly |
| SRC-0002 | Legendary musician Ray Charles dies at 73 | Associated Press (Seattle Times archive) | other |
| SRC-0003 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review. |
| provenance review | not_started | Recent-death rule: only what Charles made public and what was reported at his death is used, from the New Georgia Encyclopedia and the AP obituary. The cause of his blindness is graded R. |
| safe messaging review | not_started | Substance-use claims are marked sensitive; recovery is described in person-first, non-stigmatizing language; the safety assessment records no current risk and gives the 988 Suicide & Crisis Lifeline; death recorded without detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.